Mercer Global Advisors
MRKR icon

Mercer Global Advisors’s Marker Therapeutics MRKR Stock Holding History

Mercer Global Advisors’s Portfolio MRKR Stock Details MRKR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-4,500
Closed -$20K – 1885
2022
Q1 		$20K Buy
+4,500
New +$25.7K ﹤0.01% 1855
2020
Q4 		– Sell
-2,293
Closed -$34K – 1377
2020
Q3 		$34K Buy
+2,293
New +$41.8K ﹤0.01% 1216

Other funds holding MRKR

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ACM
ACT Capital Management Wayne, Pennsylvania $153M AUM
AAM
AR Asset Management West Hollywood, California $517M AUM 18.31% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
MAA
Matrix Asset Advisors White Plains, New York $1.23B AUM 26.4% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Mercer Global Advisors's MRKR Position: Q2 2022 in Review

Mercer Global Advisors sold out of Marker Therapeutics (MRKR) in Q2 2022, closing a stake of 4,500 shares — an estimated $20K sold.

Mercer Global Advisors first reported a position in MRKR in Q3 2020 and held it in 2 quarters. The position peaked at $34K in Q3 2020. 48 funds tracked by Wall St. Rank hold MRKR as of Q2 2022.

  • Mercer Global Advisors reported no remaining Marker Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Mercer Global Advisors sold 4,500 Marker Therapeutics shares in Q2 2022, an estimated $20K.
  • Mercer Global Advisors first reported a position in Marker Therapeutics in Q3 2020 and held it in 2 quarters.
  • Mercer Global Advisors's Marker Therapeutics position peaked at $34K in Q3 2020.
  • 48 funds tracked by Wall St. Rank held Marker Therapeutics as of Q2 2022.

Based on Mercer Global Advisors's 13F filing for Q2 2022, filed 10 Aug 2022.